Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
SWOG-S0931 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study III Signal Transduction Inhibitor everolimus
ECOG-E1808 A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features II Angiogenesis Inhibitor, Chemotherapy, Signal Transduction Inhibitor gemcitabine; sunitinib
UPCC-07811 Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma I / II Signal Transduction Inhibitor everolimus; hydroxychloroquine
UPCC-24213 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies I / II Chemotherapy, Signal Transduction Inhibitor paclitaxel; BBI608
CO-338-010 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I / II Signal Transduction Inhibitor rucaparib
UPCC-02812 Phase 1b Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma I Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor bevacizumab; CRLX101
P07990 Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma I Immunotherapy (Monoclonal Antibody) MK-3475 (Immunotherapy : PD-1 inhibitor)
3475-028 Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors I Immunotherapy, Signal Transduction Inhibitor MK-3475 (Immunotherapy : PD-1 inhibitor)
UPCC-06914 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors I Signal Transduction Inhibitor CB-839
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
UPCC-13213 A Phase 1B Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors I Chemotherapy gemcitabine; nab-paclitaxel; INCB039110
UPCC-34809 Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma 0 Signal Transduction Inhibitor pazopanib
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-11111 A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
UPCC 01914 Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors Not Specified Pain Management Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood Test Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
CLDE225A2112 A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors I Other warfarin; bupropion
UPCC-07913 A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors I Chemotherapy, Signal Transduction Inhibitor docetaxel; carboplatin; gemcitabine; paclitaxel; MLN4924
Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable